Primary liver cancer
Conditions
Interventions
Group A:adefovir treatment (Glaxo Smith Kline, Adefovir Dipivoxil Tablets, 10 mg p.o. Qd)
Group B:no antiviral treatment
Sponsors
Oriental Department of Liver and Gall Surgery Hospital
Eligibility
Sex/Gender
All
Age
16 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. age >= 16y; 2. primary liver cancer patients with HBeAg (+) or HBVDNA >=10^5 copies/ml (PCR method); 3. liver function before surgery: Child A; 4. Clinical stage of primary liver cancer: T1N0M0 or T2N0M0 I or II stage); 5. pathologically diagnosed chronic hepatitis after surgery; 6. pathologically diagnosed primary liver cancer after surgery.
Exclusion criteria
Exclusion criteria: 1. combined infection of HIV, HCV or HDV; 2. received interferon, thymic peptide or other antiviral activity medicines (like entecavi, lamivudine, etc.) within 24 weeks when allocation; 3. received anti-HIV nucleoside or nucleoside analogue medicine more than 12 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse of cancer;Quality of life;Survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum HBVDNA level;Improvemt of AFP;HBeAg negative conversion rate;improvement of histology;Improvement of liver fuction; | — |
Countries
China
Contacts
Public ContactGang Huang
Outcome results
None listed